STRASBOURG, France, Oct. 10 /CNW/ - Transgene S.A. (Eurolist Paris:
FR0005175080) announces that cash, cash equivalents and short term investments
totaled EUR 119 million at September 30, 2007 compared to EUR 114.3 million at
June 30, 2007 (unaudited figures, IAS/IFRS).
For the first nine months of 2007, cash, cash equivalents and short term
investments increased by EUR 98.7 million. This was mainly due to payments
received from the partnership agreement with Roche (EUR 23 million), the
capital increase carried out in June and July 2007 (net proceeds: EUR 95.3
million) and cash expenditures of EUR 19.6 million.
Transgene is a France-based biopharmaceutical company dedicated to the
development of therapeutic vaccines and immunotherapeutic products in oncology
and infectious diseases. The company has one product which has completed Phase
II trials (TG4001/R3484), two compounds in Phase II trials (TG4010 and TG1042)
and one compound in Phase I studies (TG4040).
Transgene has concluded a strategic partnership agreement with Roche for
the development of its TG4001/R3484 therapeutic vaccine to treat HPV-mediated
diseases. Transgene has bio-manufacturing capacities for viral-based vectors
and technologies available for out-licensing. Additional information about
Transgene is available on the Internet at http://www.transgene.fr.
For further information:
For further information: Investor contacts: Transgene, Philippe Poncet,
Chief Financial Officer, Phone: +33-3-88-27-91-21, Press contacts: Capital
MS&L, Mary Clark, Anna Mitchell, Phone: +44-20-7307-5330,